Olga Lomovskaya

Dr. Lomovskaya has over 25 years of experience in antibiotic R&D as a world-recognized expert in the field of antimicrobial resistance. Her industry career started at Microcide where she pioneered the field of understanding multi-drug resistant efflux pumps and potential therapeutic use of inhibitors. At Mpex, she oversaw key microbiology studies for Quinsair (inhaled levofloxacin) approval in cystic fibrosis. Following Mpex, she joined Rempex (later acquired by The Medicines Company) and led the efforts to discover novel beta-lactamase inhibitors and oversaw critical microbiology studies that supported the development and regulatory approval of Vabomere (meropenem-vaborbactam). Dr. Lomovskaya is an inventor on over 20 patents and patent applications, authored over 50 original papers, review articles, and book chapters. In 2018 Dr. Lomovskaya was elected as a fellow of the American Academy of Microbiology. She received her Ph.D. in molecular genetics from the Institute of Molecular Genetics, Russian Academy of Sciences, and her M.S. in molecular biology from Moscow State University, with post-doctoral research appointments at MIT, Cal Tech, and Stanford.